Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 121 | 2024 | 1037 | 15.240 |
Why?
|
Colonic Neoplasms | 77 | 2024 | 157 | 7.390 |
Why?
|
Colorectal Neoplasms | 65 | 2022 | 656 | 6.420 |
Why?
|
Neoplasm Recurrence, Local | 45 | 2022 | 249 | 6.300 |
Why?
|
Body Mass Index | 70 | 2024 | 974 | 6.150 |
Why?
|
Obesity | 49 | 2024 | 855 | 5.730 |
Why?
|
Middle Aged | 337 | 2024 | 8284 | 5.570 |
Why?
|
Postmenopause | 69 | 2024 | 267 | 5.110 |
Why?
|
Female | 382 | 2024 | 13136 | 5.050 |
Why?
|
Aged | 277 | 2024 | 6417 | 4.990 |
Why?
|
Diet | 74 | 2022 | 371 | 4.960 |
Why?
|
Humans | 422 | 2024 | 18430 | 4.810 |
Why?
|
Risk Factors | 165 | 2024 | 3449 | 3.940 |
Why?
|
Weight Gain | 20 | 2020 | 181 | 3.510 |
Why?
|
Rectal Neoplasms | 35 | 2020 | 67 | 3.490 |
Why?
|
Proportional Hazards Models | 75 | 2022 | 743 | 3.390 |
Why?
|
Neoplasms | 22 | 2024 | 457 | 3.350 |
Why?
|
Adiposity | 10 | 2024 | 67 | 3.340 |
Why?
|
Adult | 206 | 2024 | 7910 | 3.340 |
Why?
|
Prognosis | 55 | 2024 | 624 | 3.110 |
Why?
|
Survivors | 21 | 2016 | 158 | 2.980 |
Why?
|
Hot Flashes | 20 | 2020 | 39 | 2.950 |
Why?
|
Neoplasm Staging | 41 | 2022 | 337 | 2.870 |
Why?
|
Weight Loss | 19 | 2024 | 321 | 2.690 |
Why?
|
Feeding Behavior | 33 | 2020 | 168 | 2.310 |
Why?
|
Exercise | 28 | 2024 | 495 | 2.310 |
Why?
|
Polymorphism, Single Nucleotide | 43 | 2019 | 412 | 2.250 |
Why?
|
Cohort Studies | 64 | 2022 | 2672 | 2.170 |
Why?
|
Cardiovascular Diseases | 15 | 2023 | 630 | 2.090 |
Why?
|
Women's Health | 31 | 2024 | 207 | 2.080 |
Why?
|
Life Style | 38 | 2022 | 342 | 2.060 |
Why?
|
Male | 175 | 2024 | 10440 | 2.010 |
Why?
|
Surveys and Questionnaires | 58 | 2020 | 1389 | 2.010 |
Why?
|
Body Composition | 13 | 2024 | 82 | 1.950 |
Why?
|
Estrogens | 18 | 2018 | 73 | 1.900 |
Why?
|
Genetic Predisposition to Disease | 42 | 2019 | 414 | 1.840 |
Why?
|
Dietary Fats | 22 | 2013 | 92 | 1.830 |
Why?
|
California | 57 | 2020 | 2365 | 1.820 |
Why?
|
Follow-Up Studies | 52 | 2019 | 1269 | 1.790 |
Why?
|
Carcinoma, Ductal, Breast | 6 | 2015 | 57 | 1.780 |
Why?
|
Cause of Death | 11 | 2021 | 185 | 1.770 |
Why?
|
Case-Control Studies | 86 | 2019 | 1173 | 1.760 |
Why?
|
Dietary Supplements | 14 | 2015 | 88 | 1.700 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2015 | 55 | 1.690 |
Why?
|
Prospective Studies | 41 | 2020 | 1314 | 1.660 |
Why?
|
Muscle, Skeletal | 10 | 2024 | 32 | 1.650 |
Why?
|
Odds Ratio | 50 | 2019 | 701 | 1.600 |
Why?
|
Estrogen Replacement Therapy | 18 | 2016 | 104 | 1.560 |
Why?
|
United States | 69 | 2021 | 4164 | 1.520 |
Why?
|
Diabetes, Gestational | 11 | 2018 | 339 | 1.470 |
Why?
|
Body Weight | 15 | 2021 | 223 | 1.450 |
Why?
|
Mortality | 9 | 2021 | 123 | 1.410 |
Why?
|
Genetic Variation | 15 | 2016 | 87 | 1.380 |
Why?
|
Survival Analysis | 18 | 2019 | 226 | 1.380 |
Why?
|
Menopause | 11 | 2020 | 72 | 1.370 |
Why?
|
Risk Assessment | 40 | 2020 | 1143 | 1.360 |
Why?
|
Aged, 80 and over | 34 | 2024 | 2003 | 1.340 |
Why?
|
Incidence | 43 | 2017 | 1314 | 1.320 |
Why?
|
Biomarkers, Tumor | 11 | 2016 | 146 | 1.320 |
Why?
|
Quality of Life | 13 | 2024 | 529 | 1.310 |
Why?
|
Alcohol Drinking | 16 | 2020 | 375 | 1.240 |
Why?
|
Diet, Fat-Restricted | 18 | 2009 | 38 | 1.200 |
Why?
|
Receptors, Estrogen | 7 | 2017 | 58 | 1.190 |
Why?
|
Energy Intake | 25 | 2020 | 103 | 1.190 |
Why?
|
Young Adult | 29 | 2019 | 2518 | 1.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2019 | 182 | 1.180 |
Why?
|
Overweight | 12 | 2022 | 276 | 1.170 |
Why?
|
Genotype | 51 | 2018 | 253 | 1.170 |
Why?
|
Smoking | 20 | 2017 | 494 | 1.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 50 | 1.140 |
Why?
|
Estradiol | 7 | 2018 | 24 | 1.140 |
Why?
|
Social Support | 6 | 2020 | 214 | 1.120 |
Why?
|
Diet Records | 19 | 2021 | 36 | 1.070 |
Why?
|
Randomized Controlled Trials as Topic | 21 | 2020 | 342 | 1.070 |
Why?
|
Receptors, Progesterone | 7 | 2017 | 52 | 1.060 |
Why?
|
Polymorphism, Genetic | 24 | 2012 | 78 | 1.060 |
Why?
|
Ethnic Groups | 11 | 2016 | 501 | 1.050 |
Why?
|
Genome-Wide Association Study | 19 | 2018 | 252 | 1.040 |
Why?
|
Vitamin D | 12 | 2013 | 80 | 1.040 |
Why?
|
Cancer Survivors | 5 | 2024 | 89 | 1.020 |
Why?
|
Sarcopenia | 3 | 2024 | 11 | 1.000 |
Why?
|
Dairy Products | 6 | 2013 | 23 | 0.980 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 14 | 2015 | 68 | 0.980 |
Why?
|
Diet Surveys | 17 | 2020 | 58 | 0.980 |
Why?
|
Vitamins | 6 | 2022 | 65 | 0.950 |
Why?
|
Time Factors | 26 | 2017 | 1136 | 0.950 |
Why?
|
Treatment Outcome | 24 | 2020 | 1296 | 0.940 |
Why?
|
Soy Foods | 4 | 2013 | 10 | 0.930 |
Why?
|
Multivariate Analysis | 15 | 2020 | 598 | 0.920 |
Why?
|
Logistic Models | 37 | 2020 | 962 | 0.910 |
Why?
|
Adolescent | 30 | 2019 | 3798 | 0.900 |
Why?
|
Carotenoids | 17 | 2011 | 29 | 0.880 |
Why?
|
Vegetables | 22 | 2020 | 87 | 0.880 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 65 | 0.870 |
Why?
|
Retrospective Studies | 19 | 2024 | 2550 | 0.870 |
Why?
|
Inflammation | 8 | 2024 | 63 | 0.870 |
Why?
|
Continental Population Groups | 13 | 2016 | 315 | 0.850 |
Why?
|
Mutation | 16 | 2011 | 132 | 0.840 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 16 | 0.840 |
Why?
|
Registries | 16 | 2020 | 490 | 0.830 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2022 | 26 | 0.830 |
Why?
|
Neoplasm Invasiveness | 11 | 2017 | 83 | 0.830 |
Why?
|
Medroxyprogesterone Acetate | 6 | 2010 | 16 | 0.820 |
Why?
|
Comorbidity | 14 | 2020 | 619 | 0.810 |
Why?
|
Liver Neoplasms | 1 | 2022 | 42 | 0.810 |
Why?
|
Estrogen Receptor alpha | 4 | 2015 | 27 | 0.800 |
Why?
|
Kaplan-Meier Estimate | 10 | 2017 | 131 | 0.790 |
Why?
|
Health Behavior | 13 | 2010 | 374 | 0.780 |
Why?
|
Tomography, X-Ray Computed | 9 | 2022 | 208 | 0.770 |
Why?
|
Endometrial Neoplasms | 6 | 2020 | 39 | 0.760 |
Why?
|
Serotonin Uptake Inhibitors | 5 | 2015 | 74 | 0.760 |
Why?
|
Age Factors | 19 | 2020 | 965 | 0.740 |
Why?
|
Epidemiologic Methods | 9 | 2017 | 87 | 0.740 |
Why?
|
Adenoma | 14 | 2013 | 100 | 0.740 |
Why?
|
Taxoids | 2 | 2020 | 8 | 0.730 |
Why?
|
Metabolic Equivalent | 2 | 2020 | 8 | 0.730 |
Why?
|
Frailty | 1 | 2020 | 9 | 0.730 |
Why?
|
Anthracyclines | 2 | 2020 | 16 | 0.730 |
Why?
|
Biomarkers | 14 | 2024 | 308 | 0.710 |
Why?
|
Bridged-Ring Compounds | 1 | 2020 | 4 | 0.710 |
Why?
|
Depression | 8 | 2022 | 518 | 0.690 |
Why?
|
Intra-Abdominal Fat | 6 | 2024 | 15 | 0.690 |
Why?
|
Cholecalciferol | 4 | 2012 | 15 | 0.690 |
Why?
|
Tissue Distribution | 1 | 2019 | 6 | 0.690 |
Why?
|
Prostatic Neoplasms | 5 | 2010 | 298 | 0.680 |
Why?
|
Diabetes Mellitus | 9 | 2022 | 530 | 0.680 |
Why?
|
Risk | 26 | 2019 | 552 | 0.680 |
Why?
|
Motor Activity | 9 | 2014 | 215 | 0.670 |
Why?
|
Survival Rate | 17 | 2019 | 269 | 0.660 |
Why?
|
Gene-Environment Interaction | 6 | 2017 | 20 | 0.660 |
Why?
|
Double-Blind Method | 19 | 2015 | 165 | 0.660 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2018 | 7 | 0.650 |
Why?
|
Aspirin | 10 | 2015 | 67 | 0.650 |
Why?
|
Calcium, Dietary | 8 | 2012 | 28 | 0.640 |
Why?
|
Venlafaxine Hydrochloride | 5 | 2015 | 37 | 0.640 |
Why?
|
Hormone Replacement Therapy | 6 | 2010 | 28 | 0.630 |
Why?
|
DNA, Neoplasm | 7 | 2013 | 21 | 0.620 |
Why?
|
Pregnancy | 19 | 2022 | 1516 | 0.620 |
Why?
|
Dietary Fiber | 19 | 2014 | 60 | 0.620 |
Why?
|
Social Networking | 3 | 2013 | 20 | 0.620 |
Why?
|
Research Design | 9 | 2020 | 402 | 0.600 |
Why?
|
Signal Transduction | 6 | 2018 | 30 | 0.600 |
Why?
|
Gene Expression Profiling | 2 | 2014 | 34 | 0.590 |
Why?
|
Yoga | 7 | 2017 | 26 | 0.590 |
Why?
|
Receptor, ErbB-2 | 5 | 2017 | 48 | 0.580 |
Why?
|
Fruit | 19 | 2020 | 79 | 0.570 |
Why?
|
Pregnancy Trimesters | 1 | 2016 | 29 | 0.560 |
Why?
|
Medication Adherence | 1 | 2020 | 267 | 0.560 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2012 | 65 | 0.560 |
Why?
|
Receptors, Calcitriol | 10 | 2010 | 13 | 0.550 |
Why?
|
European Continental Ancestry Group | 21 | 2016 | 554 | 0.540 |
Why?
|
Maternal Exposure | 1 | 2016 | 60 | 0.540 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 131 | 0.530 |
Why?
|
Energy Metabolism | 10 | 2011 | 50 | 0.530 |
Why?
|
Lymph Nodes | 1 | 2016 | 17 | 0.530 |
Why?
|
Prenatal Care | 2 | 2016 | 134 | 0.530 |
Why?
|
Sex Factors | 24 | 2020 | 661 | 0.530 |
Why?
|
Antioxidants | 7 | 2011 | 40 | 0.520 |
Why?
|
Obesity, Abdominal | 3 | 2022 | 11 | 0.520 |
Why?
|
Adipose Tissue | 7 | 2024 | 60 | 0.520 |
Why?
|
Caffeine | 6 | 1999 | 18 | 0.510 |
Why?
|
Medical Records | 1 | 2015 | 106 | 0.510 |
Why?
|
Patient Compliance | 9 | 2014 | 318 | 0.510 |
Why?
|
Eating | 8 | 2020 | 38 | 0.510 |
Why?
|
Vitamin E | 6 | 2011 | 20 | 0.500 |
Why?
|
Sex Hormone-Binding Globulin | 3 | 2014 | 23 | 0.490 |
Why?
|
Microsatellite Instability | 10 | 2015 | 16 | 0.490 |
Why?
|
Confidence Intervals | 13 | 2016 | 253 | 0.490 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2016 | 159 | 0.480 |
Why?
|
China | 7 | 2016 | 130 | 0.480 |
Why?
|
Algorithms | 2 | 2015 | 241 | 0.480 |
Why?
|
Utah | 15 | 2014 | 33 | 0.480 |
Why?
|
Tumor Suppressor Protein p53 | 9 | 2011 | 20 | 0.480 |
Why?
|
Chi-Square Distribution | 11 | 2017 | 160 | 0.480 |
Why?
|
Anticarcinogenic Agents | 4 | 2013 | 14 | 0.470 |
Why?
|
Mammography | 5 | 2015 | 174 | 0.460 |
Why?
|
Progestins | 5 | 2016 | 28 | 0.460 |
Why?
|
Severity of Illness Index | 7 | 2020 | 476 | 0.460 |
Why?
|
Carcinoma, Basal Cell | 1 | 2014 | 24 | 0.460 |
Why?
|
Bone Density Conservation Agents | 3 | 2011 | 55 | 0.450 |
Why?
|
African Americans | 16 | 2016 | 490 | 0.450 |
Why?
|
Breast Feeding | 1 | 2015 | 133 | 0.440 |
Why?
|
Isoflavones | 2 | 2013 | 14 | 0.440 |
Why?
|
Activities of Daily Living | 2 | 2010 | 96 | 0.440 |
Why?
|
C-Reactive Protein | 6 | 2024 | 58 | 0.430 |
Why?
|
Cachexia | 3 | 2023 | 3 | 0.430 |
Why?
|
Recurrence | 11 | 2014 | 187 | 0.430 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2014 | 760 | 0.430 |
Why?
|
Thinness | 2 | 2013 | 29 | 0.430 |
Why?
|
Interleukin-6 | 4 | 2024 | 26 | 0.430 |
Why?
|
Bariatric Surgery | 4 | 2024 | 130 | 0.420 |
Why?
|
Drug Administration Schedule | 5 | 2017 | 100 | 0.420 |
Why?
|
Guideline Adherence | 5 | 2021 | 162 | 0.420 |
Why?
|
Hypertension | 4 | 2022 | 524 | 0.420 |
Why?
|
Absorptiometry, Photon | 3 | 2024 | 52 | 0.420 |
Why?
|
Transforming Growth Factor alpha | 1 | 2012 | 1 | 0.420 |
Why?
|
Fatty Acids, Omega-3 | 5 | 2015 | 22 | 0.420 |
Why?
|
Sleep Initiation and Maintenance Disorders | 5 | 2020 | 39 | 0.420 |
Why?
|
Meat | 8 | 2014 | 27 | 0.410 |
Why?
|
Estrogen Receptor Modulators | 1 | 2012 | 2 | 0.410 |
Why?
|
Health Status | 5 | 2009 | 328 | 0.410 |
Why?
|
Adenomatous Polyps | 8 | 2008 | 15 | 0.410 |
Why?
|
Cyclohexanols | 4 | 2015 | 36 | 0.400 |
Why?
|
Databases, Factual | 5 | 2017 | 327 | 0.400 |
Why?
|
CpG Islands | 12 | 2011 | 22 | 0.390 |
Why?
|
Disease-Free Survival | 8 | 2016 | 57 | 0.390 |
Why?
|
Folic Acid | 5 | 2022 | 35 | 0.390 |
Why?
|
DNA Methylation | 10 | 2011 | 42 | 0.390 |
Why?
|
Colonic Polyps | 9 | 2008 | 35 | 0.380 |
Why?
|
Proto-Oncogene Proteins | 9 | 2011 | 36 | 0.370 |
Why?
|
Patient Selection | 7 | 2019 | 198 | 0.370 |
Why?
|
Fatigue | 2 | 2020 | 35 | 0.360 |
Why?
|
Epigenesis, Genetic | 5 | 2010 | 26 | 0.360 |
Why?
|
Leucovorin | 2 | 2022 | 5 | 0.360 |
Why?
|
Fluorouracil | 2 | 2022 | 12 | 0.360 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 69 | 0.350 |
Why?
|
Pregnancy Complications | 3 | 2020 | 193 | 0.350 |
Why?
|
Mass Screening | 3 | 2009 | 690 | 0.350 |
Why?
|
Perimenopause | 5 | 2015 | 11 | 0.350 |
Why?
|
Dietary Proteins | 5 | 2015 | 20 | 0.340 |
Why?
|
Coronary Disease | 10 | 2006 | 185 | 0.330 |
Why?
|
Hispanic Americans | 12 | 2020 | 428 | 0.330 |
Why?
|
Colectomy | 2 | 2020 | 27 | 0.330 |
Why?
|
Calcium Compounds | 1 | 2008 | 4 | 0.330 |
Why?
|
Proto-Oncogene Proteins B-raf | 7 | 2009 | 16 | 0.330 |
Why?
|
Prevalence | 10 | 2017 | 911 | 0.330 |
Why?
|
ras Proteins | 9 | 2011 | 24 | 0.320 |
Why?
|
Sickness Impact Profile | 1 | 2008 | 28 | 0.320 |
Why?
|
Calcium | 5 | 2012 | 34 | 0.320 |
Why?
|
Ovarian Neoplasms | 3 | 2020 | 50 | 0.320 |
Why?
|
Reproducibility of Results | 10 | 2016 | 399 | 0.320 |
Why?
|
Ibuprofen | 2 | 2009 | 9 | 0.310 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2008 | 9 | 0.310 |
Why?
|
Environment | 4 | 2019 | 51 | 0.310 |
Why?
|
Multiple Myeloma | 2 | 2023 | 11 | 0.310 |
Why?
|
Psychometrics | 1 | 2008 | 124 | 0.310 |
Why?
|
Tamoxifen | 3 | 2010 | 60 | 0.310 |
Why?
|
Insulin Resistance | 4 | 2014 | 129 | 0.310 |
Why?
|
Arylamine N-Acetyltransferase | 8 | 2014 | 10 | 0.300 |
Why?
|
Cholesterol | 10 | 2023 | 112 | 0.300 |
Why?
|
Adenocarcinoma | 4 | 2016 | 177 | 0.300 |
Why?
|
Nutrition Assessment | 8 | 2009 | 27 | 0.300 |
Why?
|
Insurance Carriers | 1 | 2007 | 6 | 0.300 |
Why?
|
Organizations, Nonprofit | 1 | 2007 | 11 | 0.300 |
Why?
|
Sleep | 4 | 2017 | 57 | 0.300 |
Why?
|
Analysis of Variance | 5 | 2018 | 167 | 0.300 |
Why?
|
Sigmoidoscopy | 1 | 2007 | 67 | 0.290 |
Why?
|
Models, Statistical | 4 | 2017 | 185 | 0.290 |
Why?
|
Basal Metabolism | 2 | 2004 | 5 | 0.290 |
Why?
|
Neovascularization, Pathologic | 2 | 2017 | 3 | 0.280 |
Why?
|
Alleles | 7 | 2014 | 95 | 0.280 |
Why?
|
Cell Proliferation | 4 | 2020 | 20 | 0.280 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2006 | 9 | 0.280 |
Why?
|
Outcome Assessment (Health Care) | 5 | 2018 | 254 | 0.280 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2006 | 17 | 0.280 |
Why?
|
Carcinoma | 3 | 2011 | 27 | 0.280 |
Why?
|
Lutein | 5 | 2010 | 7 | 0.270 |
Why?
|
Prepaid Health Plans | 1 | 2006 | 22 | 0.270 |
Why?
|
Blood Glucose | 7 | 2014 | 346 | 0.270 |
Why?
|
Genes, p53 | 5 | 2010 | 7 | 0.270 |
Why?
|
Genetic Loci | 4 | 2014 | 60 | 0.270 |
Why?
|
Hypolipidemic Agents | 1 | 2006 | 44 | 0.270 |
Why?
|
Residence Characteristics | 5 | 2016 | 256 | 0.270 |
Why?
|
Combined Modality Therapy | 3 | 2016 | 150 | 0.270 |
Why?
|
Adaptor Proteins, Signal Transducing | 7 | 2009 | 15 | 0.260 |
Why?
|
Food | 4 | 2006 | 31 | 0.260 |
Why?
|
Colonoscopy | 7 | 2018 | 268 | 0.260 |
Why?
|
Asian Americans | 6 | 2016 | 182 | 0.260 |
Why?
|
Xanthophylls | 4 | 2010 | 6 | 0.260 |
Why?
|
DNA Repair | 2 | 2019 | 10 | 0.260 |
Why?
|
RNA, Messenger | 3 | 2014 | 80 | 0.260 |
Why?
|
DNA-Binding Proteins | 5 | 2019 | 31 | 0.260 |
Why?
|
Citalopram | 3 | 2015 | 14 | 0.250 |
Why?
|
Stroke | 5 | 2016 | 311 | 0.250 |
Why?
|
Colitis, Ulcerative | 2 | 2015 | 10 | 0.250 |
Why?
|
Crohn Disease | 2 | 2015 | 16 | 0.250 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 5 | 2012 | 9 | 0.250 |
Why?
|
Polymerase Chain Reaction | 8 | 2013 | 53 | 0.250 |
Why?
|
Vaginal Diseases | 3 | 2020 | 6 | 0.240 |
Why?
|
Resistance Training | 1 | 2024 | 8 | 0.240 |
Why?
|
Independent Living | 2 | 2024 | 21 | 0.240 |
Why?
|
Hand Strength | 1 | 2024 | 11 | 0.240 |
Why?
|
Health Promotion | 2 | 2020 | 294 | 0.240 |
Why?
|
Phenotype | 13 | 2011 | 148 | 0.240 |
Why?
|
Creatine | 1 | 2024 | 4 | 0.240 |
Why?
|
Cross-Sectional Studies | 11 | 2020 | 1360 | 0.240 |
Why?
|
Immunoenzyme Techniques | 2 | 2014 | 20 | 0.230 |
Why?
|
Myocardial Infarction | 3 | 2020 | 249 | 0.230 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 27 | 0.230 |
Why?
|
Fractures, Bone | 4 | 2006 | 91 | 0.230 |
Why?
|
Aging | 3 | 2019 | 165 | 0.230 |
Why?
|
Regression Analysis | 9 | 2011 | 319 | 0.230 |
Why?
|
Sensitivity and Specificity | 6 | 2015 | 321 | 0.230 |
Why?
|
Obesity, Morbid | 3 | 2013 | 120 | 0.230 |
Why?
|
Predictive Value of Tests | 3 | 2015 | 365 | 0.230 |
Why?
|
Brassicaceae | 3 | 2013 | 7 | 0.230 |
Why?
|
Cholesterol, HDL | 4 | 2023 | 80 | 0.230 |
Why?
|
Macular Degeneration | 2 | 2010 | 19 | 0.230 |
Why?
|
Age Distribution | 9 | 2012 | 261 | 0.230 |
Why?
|
Health Maintenance Organizations | 4 | 2012 | 479 | 0.230 |
Why?
|
Postpartum Period | 3 | 2018 | 93 | 0.230 |
Why?
|
Bias | 3 | 2018 | 111 | 0.230 |
Why?
|
Prostate-Specific Antigen | 3 | 2009 | 77 | 0.230 |
Why?
|
Calcium Carbonate | 3 | 2010 | 9 | 0.230 |
Why?
|
Socioeconomic Factors | 9 | 2016 | 673 | 0.220 |
Why?
|
Adiponectin | 1 | 2013 | 22 | 0.220 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2024 | 28 | 0.220 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 392 | 0.220 |
Why?
|
Antidepressive Agents | 2 | 2017 | 162 | 0.220 |
Why?
|
Ideal Body Weight | 2 | 2020 | 10 | 0.210 |
Why?
|
Transforming Growth Factor beta | 3 | 2011 | 9 | 0.210 |
Why?
|
Electronic Health Records | 3 | 2018 | 747 | 0.210 |
Why?
|
Risk Reduction Behavior | 4 | 2020 | 114 | 0.210 |
Why?
|
Dietary Approaches To Stop Hypertension | 1 | 2022 | 4 | 0.210 |
Why?
|
Haplotypes | 4 | 2011 | 43 | 0.210 |
Why?
|
Men's Health | 3 | 2019 | 20 | 0.210 |
Why?
|
Glutathione Transferase | 7 | 2009 | 13 | 0.200 |
Why?
|
Prehypertension | 1 | 2012 | 22 | 0.200 |
Why?
|
Nuclear Proteins | 4 | 2009 | 11 | 0.200 |
Why?
|
Lung Neoplasms | 2 | 2020 | 259 | 0.200 |
Why?
|
Mentoring | 1 | 2022 | 28 | 0.200 |
Why?
|
Disease Progression | 2 | 2020 | 271 | 0.200 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2012 | 41 | 0.200 |
Why?
|
Cost of Illness | 2 | 2012 | 100 | 0.200 |
Why?
|
Insulin | 5 | 2011 | 208 | 0.190 |
Why?
|
Vitamin A | 3 | 2009 | 15 | 0.190 |
Why?
|
Carcinoma, Endometrioid | 2 | 2019 | 2 | 0.190 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 9 | 2011 | 25 | 0.190 |
Why?
|
Coronary Artery Disease | 4 | 2016 | 133 | 0.190 |
Why?
|
Nutrition Policy | 1 | 2021 | 18 | 0.190 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2011 | 17 | 0.190 |
Why?
|
Organ Size | 2 | 2018 | 16 | 0.190 |
Why?
|
Family Characteristics | 2 | 2012 | 54 | 0.190 |
Why?
|
Mental Recall | 8 | 2011 | 31 | 0.190 |
Why?
|
Nutritional Status | 2 | 2020 | 30 | 0.190 |
Why?
|
Wine | 3 | 2010 | 18 | 0.190 |
Why?
|
Self Report | 3 | 2016 | 256 | 0.190 |
Why?
|
Muscle Weakness | 1 | 2020 | 3 | 0.190 |
Why?
|
Recommended Dietary Allowances | 1 | 2020 | 2 | 0.180 |
Why?
|
Monocytes | 1 | 2020 | 5 | 0.180 |
Why?
|
Mobility Limitation | 1 | 2020 | 16 | 0.180 |
Why?
|
Triglycerides | 5 | 2022 | 87 | 0.180 |
Why?
|
Longitudinal Studies | 11 | 2019 | 724 | 0.180 |
Why?
|
Causality | 2 | 2019 | 43 | 0.180 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2020 | 4 | 0.180 |
Why?
|
Healthy Lifestyle | 1 | 2020 | 15 | 0.180 |
Why?
|
Leukocyte Count | 2 | 2012 | 22 | 0.180 |
Why?
|
Models, Genetic | 2 | 2018 | 24 | 0.180 |
Why?
|
Insurance Claim Review | 2 | 2017 | 70 | 0.180 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2010 | 3 | 0.180 |
Why?
|
Dietary Carbohydrates | 6 | 2011 | 27 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 73 | 0.170 |
Why?
|
Minnesota | 7 | 2011 | 54 | 0.170 |
Why?
|
Early Detection of Cancer | 2 | 2018 | 526 | 0.170 |
Why?
|
Body Weights and Measures | 2 | 2017 | 13 | 0.170 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 51 | 0.170 |
Why?
|
Heart Failure | 2 | 2016 | 398 | 0.170 |
Why?
|
Lumbosacral Region | 1 | 2019 | 2 | 0.170 |
Why?
|
Ethanol | 1 | 2019 | 23 | 0.170 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 19 | 0.170 |
Why?
|
Social Media | 1 | 2019 | 12 | 0.170 |
Why?
|
Vasomotor System | 2 | 2015 | 5 | 0.160 |
Why?
|
Glycemic Index | 3 | 2008 | 21 | 0.160 |
Why?
|
Body Constitution | 2 | 1998 | 39 | 0.160 |
Why?
|
Animals | 8 | 2020 | 261 | 0.160 |
Why?
|
Contraceptives, Oral, Hormonal | 2 | 2007 | 12 | 0.160 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2018 | 1 | 0.160 |
Why?
|
Vulva | 1 | 2018 | 1 | 0.160 |
Why?
|
Practice Guidelines as Topic | 4 | 2019 | 333 | 0.160 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 133 | 0.160 |
Why?
|
Vitamin D3 24-Hydroxylase | 2 | 2016 | 2 | 0.160 |
Why?
|
Cholesterol, LDL | 3 | 2022 | 125 | 0.160 |
Why?
|
Plasma | 1 | 2008 | 1 | 0.160 |
Why?
|
Melanoma | 1 | 2018 | 37 | 0.160 |
Why?
|
Fertility | 1 | 1998 | 10 | 0.150 |
Why?
|
Survivorship | 1 | 2018 | 9 | 0.150 |
Why?
|
Drug Therapy, Combination | 3 | 2016 | 119 | 0.150 |
Why?
|
Models, Biological | 1 | 2018 | 32 | 0.150 |
Why?
|
Diet, Reducing | 2 | 2012 | 27 | 0.150 |
Why?
|
Counseling | 5 | 2007 | 197 | 0.150 |
Why?
|
Precision Medicine | 1 | 2018 | 29 | 0.150 |
Why?
|
Ascorbic Acid | 3 | 2011 | 19 | 0.150 |
Why?
|
Genomics | 1 | 2018 | 66 | 0.150 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 3 | 0.150 |
Why?
|
Sunlight | 4 | 2010 | 16 | 0.150 |
Why?
|
Plants, Edible | 1 | 1997 | 6 | 0.150 |
Why?
|
Gene Frequency | 6 | 2015 | 48 | 0.150 |
Why?
|
Withholding Treatment | 1 | 2017 | 26 | 0.150 |
Why?
|
Affect | 2 | 2014 | 26 | 0.150 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2007 | 12 | 0.150 |
Why?
|
Multicenter Studies as Topic | 8 | 2008 | 91 | 0.150 |
Why?
|
Infant, Newborn | 3 | 2016 | 872 | 0.150 |
Why?
|
Weight Reduction Programs | 1 | 2018 | 60 | 0.150 |
Why?
|
Acculturation | 2 | 2015 | 22 | 0.150 |
Why?
|
Androgens | 1 | 2007 | 13 | 0.140 |
Why?
|
Transcriptome | 1 | 2017 | 22 | 0.140 |
Why?
|
Actigraphy | 1 | 2017 | 17 | 0.140 |
Why?
|
beta Carotene | 5 | 2009 | 17 | 0.140 |
Why?
|
Lipids | 3 | 1996 | 78 | 0.140 |
Why?
|
Thymidylate Synthase | 2 | 2007 | 2 | 0.140 |
Why?
|
Abdominal Fat | 1 | 2016 | 15 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2017 | 38 | 0.140 |
Why?
|
Lymphatic Metastasis | 3 | 2012 | 29 | 0.140 |
Why?
|
Protective Factors | 1 | 2016 | 33 | 0.140 |
Why?
|
Heart Valve Diseases | 1 | 2016 | 20 | 0.140 |
Why?
|
Receptors, Androgen | 2 | 2006 | 13 | 0.140 |
Why?
|
Arrhythmias, Cardiac | 1 | 2016 | 32 | 0.140 |
Why?
|
Factor Analysis, Statistical | 3 | 2008 | 36 | 0.130 |
Why?
|
Social Isolation | 1 | 2016 | 16 | 0.130 |
Why?
|
Heart Rate | 1 | 2015 | 40 | 0.130 |
Why?
|
DNA Repair Enzymes | 2 | 2019 | 6 | 0.130 |
Why?
|
Tocopherols | 3 | 2010 | 5 | 0.130 |
Why?
|
Family | 2 | 2012 | 120 | 0.130 |
Why?
|
Bone Morphogenetic Protein Receptors, Type II | 1 | 2015 | 1 | 0.130 |
Why?
|
Bone Morphogenetic Protein 1 | 1 | 2015 | 1 | 0.130 |
Why?
|
Genetic Association Studies | 5 | 2015 | 35 | 0.130 |
Why?
|
Mendelian Randomization Analysis | 1 | 2015 | 24 | 0.130 |
Why?
|
PPAR gamma | 2 | 2005 | 10 | 0.130 |
Why?
|
Carcinoma, Lobular | 2 | 2012 | 12 | 0.130 |
Why?
|
Drug Combinations | 3 | 2010 | 43 | 0.130 |
Why?
|
MutL Protein Homolog 1 | 5 | 2019 | 8 | 0.130 |
Why?
|
Docosahexaenoic Acids | 2 | 2014 | 7 | 0.120 |
Why?
|
Premenopause | 2 | 2020 | 27 | 0.120 |
Why?
|
Emigration and Immigration | 1 | 2015 | 15 | 0.120 |
Why?
|
Anthropometry | 3 | 2024 | 67 | 0.120 |
Why?
|
Eicosapentaenoic Acid | 2 | 2014 | 9 | 0.120 |
Why?
|
Fertilization | 1 | 1994 | 3 | 0.120 |
Why?
|
Depressive Disorder | 1 | 2017 | 231 | 0.120 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2013 | 9 | 0.120 |
Why?
|
MicroRNAs | 1 | 2014 | 17 | 0.120 |
Why?
|
Smoking Cessation | 1 | 1996 | 199 | 0.120 |
Why?
|
STAT3 Transcription Factor | 1 | 2014 | 3 | 0.120 |
Why?
|
Recreation | 1 | 2015 | 37 | 0.120 |
Why?
|
Managed Care Programs | 1 | 2016 | 347 | 0.120 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 4 | 2011 | 11 | 0.120 |
Why?
|
Glaucoma | 1 | 2014 | 12 | 0.120 |
Why?
|
Body Size | 3 | 2016 | 31 | 0.120 |
Why?
|
Sampling Studies | 2 | 2010 | 55 | 0.120 |
Why?
|
Telephone | 4 | 2014 | 179 | 0.120 |
Why?
|
Behavior Therapy | 1 | 2015 | 155 | 0.120 |
Why?
|
Cyclooxygenase 1 | 1 | 2013 | 1 | 0.120 |
Why?
|
Cyclooxygenase 2 | 1 | 2013 | 7 | 0.120 |
Why?
|
Neoplasm Grading | 1 | 2014 | 49 | 0.120 |
Why?
|
Genetic Pleiotropy | 1 | 2013 | 9 | 0.110 |
Why?
|
Premenstrual Syndrome | 1 | 1993 | 2 | 0.110 |
Why?
|
Healthcare Disparities | 1 | 2016 | 211 | 0.110 |
Why?
|
Data Collection | 4 | 2002 | 275 | 0.110 |
Why?
|
Cyclin D2 | 1 | 2012 | 1 | 0.110 |
Why?
|
Epistasis, Genetic | 1 | 2012 | 3 | 0.110 |
Why?
|
Biomedical Research | 1 | 2014 | 93 | 0.110 |
Why?
|
Tumor Burden | 2 | 2012 | 20 | 0.110 |
Why?
|
Linear Models | 4 | 2018 | 243 | 0.110 |
Why?
|
Infant | 1 | 2016 | 1245 | 0.110 |
Why?
|
Progesterone Congeners | 1 | 2002 | 5 | 0.110 |
Why?
|
Vitamin D Deficiency | 1 | 2012 | 22 | 0.110 |
Why?
|
Population Groups | 1 | 2012 | 8 | 0.100 |
Why?
|
Child, Preschool | 2 | 2016 | 1478 | 0.100 |
Why?
|
Bone Density | 3 | 2006 | 96 | 0.100 |
Why?
|
Pedigree | 1 | 2012 | 58 | 0.100 |
Why?
|
Genome, Human | 1 | 2012 | 42 | 0.100 |
Why?
|
Genetic Markers | 4 | 2015 | 28 | 0.100 |
Why?
|
Glutathione Peroxidase | 1 | 2012 | 3 | 0.100 |
Why?
|
Marital Status | 1 | 2012 | 22 | 0.100 |
Why?
|
Genes, ras | 2 | 2009 | 5 | 0.100 |
Why?
|
Religion | 1 | 2012 | 14 | 0.100 |
Why?
|
Receptors, Interleukin | 1 | 2011 | 4 | 0.100 |
Why?
|
Health Surveys | 2 | 2018 | 269 | 0.100 |
Why?
|
TCF Transcription Factors | 2 | 2008 | 10 | 0.100 |
Why?
|
Metabolic Syndrome | 1 | 2012 | 80 | 0.100 |
Why?
|
Community Participation | 1 | 1991 | 33 | 0.100 |
Why?
|
Caregivers | 1 | 2012 | 126 | 0.100 |
Why?
|
Atrial Fibrillation | 1 | 2013 | 167 | 0.100 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2011 | 3 | 0.100 |
Why?
|
Nutritional Physiological Phenomena | 2 | 1991 | 17 | 0.100 |
Why?
|
Aromatase | 1 | 2011 | 10 | 0.100 |
Why?
|
Phosphoproteins | 3 | 2008 | 4 | 0.100 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2010 | 1 | 0.090 |
Why?
|
Core Binding Factor Alpha 1 Subunit | 1 | 2010 | 1 | 0.090 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2010 | 1 | 0.090 |
Why?
|
Core Binding Factor Alpha 3 Subunit | 1 | 2010 | 1 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 2 | 0.090 |
Why?
|
Beverages | 3 | 2004 | 17 | 0.090 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2010 | 7 | 0.090 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2011 | 43 | 0.090 |
Why?
|
Physical Fitness | 2 | 2002 | 76 | 0.090 |
Why?
|
Coronary Angiography | 1 | 2010 | 22 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 90 | 0.090 |
Why?
|
Calcinosis | 1 | 2010 | 40 | 0.090 |
Why?
|
Dietary Sucrose | 3 | 2006 | 12 | 0.090 |
Why?
|
Sweating | 3 | 2015 | 9 | 0.090 |
Why?
|
Smad7 Protein | 1 | 2010 | 2 | 0.090 |
Why?
|
Prostatitis | 1 | 2010 | 8 | 0.090 |
Why?
|
Preventive Health Services | 1 | 2012 | 166 | 0.090 |
Why?
|
Sex Distribution | 5 | 2012 | 198 | 0.090 |
Why?
|
Linkage Disequilibrium | 4 | 2012 | 39 | 0.090 |
Why?
|
Chemoprevention | 2 | 2007 | 12 | 0.090 |
Why?
|
Population Surveillance | 3 | 2016 | 271 | 0.090 |
Why?
|
Leukemia | 1 | 2009 | 9 | 0.090 |
Why?
|
Embryonic and Fetal Development | 1 | 1989 | 3 | 0.090 |
Why?
|
Steroid Hydroxylases | 1 | 2009 | 1 | 0.090 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 1 | 0.090 |
Why?
|
Migraine Disorders | 1 | 2010 | 16 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2009 | 25 | 0.090 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 25 | 0.090 |
Why?
|
Infant, Low Birth Weight | 1 | 1989 | 37 | 0.090 |
Why?
|
Sexually Transmitted Diseases | 1 | 2010 | 55 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 172 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 2 | 2008 | 7 | 0.080 |
Why?
|
Precancerous Conditions | 2 | 2008 | 48 | 0.080 |
Why?
|
Interviews as Topic | 6 | 2005 | 327 | 0.080 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2008 | 1 | 0.080 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 15 | 0.080 |
Why?
|
Quality Control | 5 | 2014 | 48 | 0.080 |
Why?
|
Self-Assessment | 1 | 2008 | 17 | 0.080 |
Why?
|
Observational Studies as Topic | 2 | 2019 | 49 | 0.080 |
Why?
|
Evaluation Studies as Topic | 3 | 2005 | 35 | 0.080 |
Why?
|
Fibrocystic Breast Disease | 1 | 2008 | 5 | 0.080 |
Why?
|
DNA Mismatch Repair | 1 | 2008 | 5 | 0.080 |
Why?
|
Flavonoids | 1 | 2008 | 5 | 0.080 |
Why?
|
Receptors, Leptin | 1 | 2008 | 3 | 0.080 |
Why?
|
Zeaxanthins | 3 | 2010 | 5 | 0.080 |
Why?
|
Lens Nucleus, Crystalline | 1 | 2008 | 1 | 0.080 |
Why?
|
African Continental Ancestry Group | 4 | 2009 | 166 | 0.080 |
Why?
|
Reproduction | 2 | 1998 | 12 | 0.080 |
Why?
|
Leptin | 1 | 2008 | 30 | 0.080 |
Why?
|
Cataract | 1 | 2008 | 10 | 0.080 |
Why?
|
Hysterectomy | 2 | 2006 | 30 | 0.080 |
Why?
|
Osteoporosis, Postmenopausal | 2 | 2003 | 44 | 0.070 |
Why?
|
Computational Biology | 2 | 2018 | 28 | 0.070 |
Why?
|
Mice | 2 | 2020 | 68 | 0.070 |
Why?
|
Cooking | 5 | 2005 | 17 | 0.070 |
Why?
|
Stress, Psychological | 1 | 2008 | 147 | 0.070 |
Why?
|
Dinucleoside Phosphates | 1 | 2006 | 2 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2007 | 52 | 0.070 |
Why?
|
Food Services | 1 | 1987 | 15 | 0.070 |
Why?
|
Osteoarthritis, Hip | 1 | 2006 | 8 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2006 | 10 | 0.070 |
Why?
|
Osteoarthritis, Knee | 1 | 2006 | 11 | 0.070 |
Why?
|
Microsatellite Repeats | 3 | 2015 | 10 | 0.070 |
Why?
|
Asian Continental Ancestry Group | 3 | 2012 | 90 | 0.070 |
Why?
|
Blood Pressure | 2 | 2022 | 310 | 0.070 |
Why?
|
Quantitative Trait, Heritable | 1 | 2006 | 8 | 0.070 |
Why?
|
Cluster Analysis | 2 | 2018 | 96 | 0.070 |
Why?
|
Arterial Occlusive Diseases | 1 | 2006 | 8 | 0.070 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2006 | 6 | 0.070 |
Why?
|
Carotid Artery Diseases | 1 | 2006 | 12 | 0.070 |
Why?
|
Riboflavin | 3 | 2012 | 3 | 0.070 |
Why?
|
Vitamin B 6 | 3 | 2012 | 3 | 0.070 |
Why?
|
Methionine | 3 | 2012 | 6 | 0.070 |
Why?
|
Vitamin B 12 | 3 | 2012 | 15 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 2 | 2019 | 3 | 0.070 |
Why?
|
Myocardial Revascularization | 1 | 2006 | 12 | 0.070 |
Why?
|
Estrogen Receptor beta | 1 | 2005 | 12 | 0.070 |
Why?
|
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2005 | 1 | 0.070 |
Why?
|
Membrane Transport Proteins | 1 | 2005 | 4 | 0.070 |
Why?
|
SEER Program | 2 | 2020 | 101 | 0.070 |
Why?
|
Point Mutation | 1 | 2005 | 6 | 0.070 |
Why?
|
Educational Status | 5 | 2009 | 205 | 0.070 |
Why?
|
Receptor, Insulin | 1 | 2005 | 6 | 0.060 |
Why?
|
Somatomedins | 1 | 2005 | 5 | 0.060 |
Why?
|
Risk-Taking | 1 | 2006 | 109 | 0.060 |
Why?
|
Primary Prevention | 4 | 2006 | 79 | 0.060 |
Why?
|
Epoxide Hydrolases | 1 | 2005 | 2 | 0.060 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2005 | 6 | 0.060 |
Why?
|
Epidemiologic Studies | 2 | 2005 | 32 | 0.060 |
Why?
|
Edible Grain | 3 | 2012 | 14 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2024 | 3 | 0.060 |
Why?
|
Hip Fractures | 4 | 2006 | 68 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2024 | 4 | 0.060 |
Why?
|
Statistics as Topic | 3 | 2014 | 66 | 0.060 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2024 | 12 | 0.060 |
Why?
|
Emigrants and Immigrants | 2 | 2015 | 31 | 0.060 |
Why?
|
Walking Speed | 1 | 2024 | 3 | 0.060 |
Why?
|
Postural Balance | 1 | 2024 | 11 | 0.060 |
Why?
|
Sucrose | 2 | 2005 | 7 | 0.060 |
Why?
|
Hot Temperature | 1 | 2004 | 8 | 0.060 |
Why?
|
Uterine Hemorrhage | 1 | 2004 | 9 | 0.060 |
Why?
|
Placebos | 2 | 2014 | 23 | 0.060 |
Why?
|
Micronutrients | 1 | 2004 | 9 | 0.060 |
Why?
|
Drinking | 1 | 2004 | 3 | 0.060 |
Why?
|
Early Diagnosis | 1 | 2014 | 40 | 0.060 |
Why?
|
Tea | 1 | 2003 | 8 | 0.060 |
Why?
|
Muscular Atrophy | 1 | 2023 | 2 | 0.060 |
Why?
|
Patient Education as Topic | 3 | 2014 | 214 | 0.060 |
Why?
|
Preconception Care | 1 | 2014 | 48 | 0.060 |
Why?
|
Probability | 2 | 2018 | 86 | 0.060 |
Why?
|
Multiple Organ Failure | 1 | 2023 | 12 | 0.060 |
Why?
|
Diet Therapy | 1 | 2003 | 12 | 0.060 |
Why?
|
Medical History Taking | 2 | 2003 | 37 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2013 | 23 | 0.050 |
Why?
|
Glucose | 1 | 2022 | 30 | 0.050 |
Why?
|
Anxiety | 2 | 2014 | 156 | 0.050 |
Why?
|
F2-Isoprostanes | 1 | 2002 | 1 | 0.050 |
Why?
|
Malondialdehyde | 1 | 2002 | 2 | 0.050 |
Why?
|
Abdomen | 1 | 2022 | 21 | 0.050 |
Why?
|
Lipid Peroxidation | 1 | 2002 | 4 | 0.050 |
Why?
|
Exercise Therapy | 2 | 2014 | 74 | 0.050 |
Why?
|
Oxidative Stress | 1 | 2002 | 10 | 0.050 |
Why?
|
Kidney Calculi | 2 | 2006 | 6 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2008 | 8 | 0.050 |
Why?
|
Insulin Receptor Substrate Proteins | 3 | 2008 | 5 | 0.050 |
Why?
|
Glucose Intolerance | 1 | 2012 | 45 | 0.050 |
Why?
|
Blood Pressure Determination | 1 | 2012 | 58 | 0.050 |
Why?
|
Nutrition Surveys | 2 | 2012 | 63 | 0.050 |
Why?
|
Fishes | 3 | 2010 | 10 | 0.050 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2011 | 27 | 0.050 |
Why?
|
Muscles | 1 | 2020 | 2 | 0.050 |
Why?
|
Preoperative Care | 1 | 2020 | 19 | 0.050 |
Why?
|
Coffee | 1 | 2000 | 5 | 0.050 |
Why?
|
Antigens, Ly | 1 | 2020 | 1 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 17 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2020 | 19 | 0.050 |
Why?
|
American Cancer Society | 1 | 2020 | 16 | 0.050 |
Why?
|
Morbidity | 1 | 2020 | 62 | 0.050 |
Why?
|
Glucose Tolerance Test | 1 | 2010 | 106 | 0.040 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 10 | 0.040 |
Why?
|
Serum Albumin | 1 | 2020 | 5 | 0.040 |
Why?
|
Maternal Nutritional Physiological Phenomena | 1 | 2020 | 11 | 0.040 |
Why?
|
Geriatric Assessment | 1 | 2020 | 40 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 33 | 0.040 |
Why?
|
Length of Stay | 1 | 2020 | 183 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 24 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 4 | 0.040 |
Why?
|
Cadherins | 2 | 2009 | 6 | 0.040 |
Why?
|
Carrier Proteins | 2 | 2009 | 13 | 0.040 |
Why?
|
Biological Variation, Population | 1 | 2019 | 1 | 0.040 |
Why?
|
DNA Modification Methylases | 1 | 2019 | 2 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 94 | 0.040 |
Why?
|
Carcinogenesis | 1 | 2019 | 9 | 0.040 |
Why?
|
Psychology | 1 | 2019 | 17 | 0.040 |
Why?
|
Rectum | 1 | 2019 | 12 | 0.040 |
Why?
|
Sex Characteristics | 2 | 2003 | 70 | 0.040 |
Why?
|
Colon | 1 | 2019 | 21 | 0.040 |
Why?
|
Nerve Tissue Proteins | 2 | 2009 | 21 | 0.040 |
Why?
|
Xanthines | 1 | 1999 | 6 | 0.040 |
Why?
|
Dental Caries | 1 | 1979 | 37 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2019 | 17 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2019 | 76 | 0.040 |
Why?
|
Demography | 1 | 2019 | 108 | 0.040 |
Why?
|
Tobacco Smoke Pollution | 2 | 2009 | 34 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 54 | 0.040 |
Why?
|
RNA, Long Noncoding | 1 | 2018 | 5 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2009 | 16 | 0.040 |
Why?
|
Social Environment | 1 | 2019 | 90 | 0.040 |
Why?
|
Reference Standards | 1 | 2018 | 17 | 0.040 |
Why?
|
Transcription Factor 7-Like 2 Protein | 2 | 2008 | 13 | 0.040 |
Why?
|
Pulmonary Embolism | 2 | 2004 | 44 | 0.040 |
Why?
|
Patient Readmission | 1 | 2020 | 162 | 0.040 |
Why?
|
Gels | 1 | 2018 | 2 | 0.040 |
Why?
|
Administration, Intravaginal | 1 | 2018 | 2 | 0.040 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2018 | 2 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2018 | 4 | 0.040 |
Why?
|
Body Height | 1 | 2018 | 62 | 0.040 |
Why?
|
Software | 1 | 2018 | 21 | 0.040 |
Why?
|
Pilot Projects | 1 | 2019 | 237 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2010 | 11 | 0.040 |
Why?
|
Reference Values | 3 | 2005 | 93 | 0.040 |
Why?
|
Seafood | 2 | 2010 | 8 | 0.040 |
Why?
|
Receptors, Ghrelin | 1 | 2017 | 1 | 0.040 |
Why?
|
Androgen Receptor Antagonists | 1 | 2017 | 2 | 0.040 |
Why?
|
Epidemiologic Research Design | 1 | 2008 | 24 | 0.040 |
Why?
|
Inflammation Mediators | 1 | 2017 | 7 | 0.040 |
Why?
|
ROC Curve | 1 | 2018 | 83 | 0.040 |
Why?
|
Diet, Vegetarian | 2 | 2009 | 13 | 0.040 |
Why?
|
Ghrelin | 1 | 2017 | 15 | 0.040 |
Why?
|
Computer Simulation | 1 | 2018 | 85 | 0.040 |
Why?
|
Food Preferences | 2 | 2009 | 24 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 23 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2017 | 36 | 0.040 |
Why?
|
Ethinyl Estradiol | 1 | 2007 | 4 | 0.040 |
Why?
|
Health Services | 1 | 1998 | 117 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2016 | 29 | 0.030 |
Why?
|
Sample Size | 2 | 2012 | 30 | 0.030 |
Why?
|
Arizona | 1 | 2016 | 6 | 0.030 |
Why?
|
A549 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
Caco-2 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
Calcium Oxalate | 1 | 1996 | 2 | 0.030 |
Why?
|
Diet, Protein-Restricted | 1 | 1996 | 2 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2016 | 23 | 0.030 |
Why?
|
Interleukins | 1 | 2016 | 2 | 0.030 |
Why?
|
Confounding Factors (Epidemiology) | 2 | 2006 | 99 | 0.030 |
Why?
|
Meat Products | 2 | 2006 | 3 | 0.030 |
Why?
|
Health Care Costs | 1 | 1998 | 251 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2016 | 69 | 0.030 |
Why?
|
Attitude to Health | 2 | 2008 | 177 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 41 | 0.030 |
Why?
|
Europe | 1 | 2015 | 44 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2015 | 2 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2015 | 7 | 0.030 |
Why?
|
Asia | 1 | 2015 | 15 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 24 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2014 | 38 | 0.030 |
Why?
|
Meditation | 1 | 2014 | 20 | 0.030 |
Why?
|
Postnatal Care | 1 | 2014 | 22 | 0.030 |
Why?
|
Directive Counseling | 1 | 2014 | 25 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 1993 | 10 | 0.030 |
Why?
|
Menstrual Cycle | 1 | 1993 | 8 | 0.030 |
Why?
|
Genotyping Techniques | 1 | 2013 | 26 | 0.030 |
Why?
|
Genistein | 1 | 2013 | 1 | 0.030 |
Why?
|
MCF-7 Cells | 1 | 2013 | 4 | 0.030 |
Why?
|
Nipples | 1 | 2013 | 2 | 0.030 |
Why?
|
Isothiocyanates | 1 | 2013 | 8 | 0.030 |
Why?
|
Phytoestrogens | 1 | 2013 | 7 | 0.030 |
Why?
|
Cell Cycle | 1 | 2013 | 4 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2013 | 6 | 0.030 |
Why?
|
Hormones | 1 | 2013 | 17 | 0.030 |
Why?
|
5-Lipoxygenase-Activating Proteins | 1 | 2013 | 4 | 0.030 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 2013 | 4 | 0.030 |
Why?
|
Arachidonate 15-Lipoxygenase | 1 | 2013 | 4 | 0.030 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2013 | 4 | 0.030 |
Why?
|
Child | 2 | 2019 | 2571 | 0.030 |
Why?
|
Laminin | 1 | 2012 | 2 | 0.030 |
Why?
|
T-Box Domain Proteins | 1 | 2012 | 4 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2014 | 232 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 38 | 0.030 |
Why?
|
DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2012 | 1 | 0.030 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 1 | 0.030 |
Why?
|
Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2012 | 1 | 0.030 |
Why?
|
Glycine Hydroxymethyltransferase | 1 | 2012 | 1 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2012 | 1 | 0.030 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2002 | 2 | 0.030 |
Why?
|
HapMap Project | 1 | 2012 | 2 | 0.030 |
Why?
|
Washington | 1 | 2013 | 388 | 0.030 |
Why?
|
Thrombosis | 1 | 2002 | 11 | 0.030 |
Why?
|
Indians, North American | 1 | 2012 | 50 | 0.030 |
Why?
|
Mutagens | 2 | 2004 | 2 | 0.030 |
Why?
|
Methods | 1 | 1991 | 7 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2011 | 1 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2011 | 1 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 1 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2011 | 1 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2011 | 2 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2011 | 2 | 0.030 |
Why?
|
Protein-Serine-Threonine Kinases | 1 | 2011 | 4 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 3 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 5 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 270 | 0.030 |
Why?
|
Random Allocation | 1 | 1991 | 41 | 0.020 |
Why?
|
Deuterium | 1 | 2011 | 3 | 0.020 |
Why?
|
Oxygen Isotopes | 1 | 2011 | 3 | 0.020 |
Why?
|
Urinalysis | 1 | 2011 | 9 | 0.020 |
Why?
|
Health Personnel | 1 | 2012 | 126 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2011 | 4 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 288 | 0.020 |
Why?
|
Health Status Indicators | 1 | 1991 | 71 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2012 | 247 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2010 | 21 | 0.020 |
Why?
|
Physical Exertion | 1 | 2010 | 22 | 0.020 |
Why?
|
Biopsy | 1 | 2010 | 75 | 0.020 |
Why?
|
X-ray Repair Cross Complementing Protein 1 | 1 | 2009 | 3 | 0.020 |
Why?
|
DNA Glycosylases | 1 | 2009 | 6 | 0.020 |
Why?
|
Introns | 1 | 2009 | 10 | 0.020 |
Why?
|
Inactivation, Metabolic | 1 | 2009 | 1 | 0.020 |
Why?
|
Proteoglycans | 1 | 2009 | 2 | 0.020 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2009 | 3 | 0.020 |
Why?
|
gamma-Tocopherol | 1 | 2009 | 1 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2009 | 46 | 0.020 |
Why?
|
Language | 1 | 2009 | 52 | 0.020 |
Why?
|
Nutritional Sciences | 2 | 2001 | 11 | 0.020 |
Why?
|
Genes, APC | 1 | 2009 | 1 | 0.020 |
Why?
|
Genes, p16 | 1 | 2009 | 1 | 0.020 |
Why?
|
Area Under Curve | 1 | 2009 | 34 | 0.020 |
Why?
|
Social Class | 1 | 2009 | 125 | 0.020 |
Why?
|
Pro-Opiomelanocortin | 1 | 2008 | 1 | 0.020 |
Why?
|
Exons | 1 | 2008 | 10 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 31 | 0.020 |
Why?
|
Alcoholic Beverages | 1 | 2008 | 14 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2008 | 23 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2008 | 21 | 0.020 |
Why?
|
Geography | 1 | 2008 | 41 | 0.020 |
Why?
|
Retinal Pigments | 1 | 2008 | 3 | 0.020 |
Why?
|
Health Services Research | 1 | 2009 | 264 | 0.020 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2007 | 2 | 0.020 |
Why?
|
Diet, Mediterranean | 1 | 2007 | 7 | 0.020 |
Why?
|
Minority Groups | 1 | 1998 | 105 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 7 | 0.020 |
Why?
|
Cryptoxanthins | 1 | 2006 | 1 | 0.020 |
Why?
|
Twins, Dizygotic | 1 | 2006 | 8 | 0.020 |
Why?
|
Twins, Monozygotic | 1 | 2006 | 12 | 0.020 |
Why?
|
Trinucleotide Repeats | 1 | 2006 | 2 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2006 | 7 | 0.020 |
Why?
|
Lower Extremity | 1 | 2006 | 13 | 0.020 |
Why?
|
Outcome and Process Assessment (Health Care) | 1 | 1987 | 110 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2006 | 23 | 0.020 |
Why?
|
Horses | 1 | 2006 | 2 | 0.020 |
Why?
|
Drug Interactions | 1 | 2006 | 20 | 0.020 |
Why?
|
Fatty Acids | 1 | 2006 | 8 | 0.020 |
Why?
|
Spinal Fractures | 1 | 2006 | 12 | 0.020 |
Why?
|
Observation | 1 | 2006 | 25 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2006 | 48 | 0.020 |
Why?
|
Reduced Folate Carrier Protein | 1 | 2005 | 1 | 0.020 |
Why?
|
Hyperplasia | 1 | 2005 | 6 | 0.020 |
Why?
|
Gonadal Steroid Hormones | 1 | 2006 | 33 | 0.020 |
Why?
|
Mutagenesis | 1 | 2005 | 4 | 0.020 |
Why?
|
Health | 1 | 2006 | 35 | 0.020 |
Why?
|
Southwestern United States | 1 | 2005 | 4 | 0.020 |
Why?
|
DNA Primers | 1 | 2005 | 7 | 0.020 |
Why?
|
Base Sequence | 1 | 2005 | 20 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2005 | 23 | 0.020 |
Why?
|
Polycyclic Aromatic Hydrocarbons | 1 | 2004 | 3 | 0.010 |
Why?
|
Beer | 1 | 2004 | 9 | 0.010 |
Why?
|
North Carolina | 1 | 2004 | 34 | 0.010 |
Why?
|
Motivation | 1 | 2005 | 137 | 0.010 |
Why?
|
Parity | 1 | 2004 | 74 | 0.010 |
Why?
|
Food Analysis | 1 | 2003 | 5 | 0.010 |
Why?
|
Hotlines | 1 | 2002 | 16 | 0.010 |
Why?
|
Brassica | 1 | 2000 | 1 | 0.010 |
Why?
|
Enzyme Induction | 1 | 2000 | 1 | 0.010 |
Why?
|
Food Coloring Agents | 1 | 1980 | 4 | 0.010 |
Why?
|
Treatment Failure | 1 | 2000 | 36 | 0.010 |
Why?
|
Behavior | 1 | 1980 | 18 | 0.010 |
Why?
|
Age of Onset | 1 | 2000 | 82 | 0.010 |
Why?
|
Poultry | 1 | 1999 | 2 | 0.010 |
Why?
|
Carcinogens | 1 | 1999 | 4 | 0.010 |
Why?
|
Cattle | 1 | 1999 | 6 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1998 | 1 | 0.010 |
Why?
|
DNA | 1 | 1999 | 25 | 0.010 |
Why?
|
Family Health | 1 | 1998 | 49 | 0.010 |
Why?
|
Environmental Exposure | 1 | 1999 | 115 | 0.010 |
Why?
|
Discriminant Analysis | 1 | 1997 | 5 | 0.010 |
Why?
|
Fluid Therapy | 1 | 1996 | 11 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1998 | 266 | 0.010 |
Why?
|
Centers for Medicare and Medicaid Services (U.S.) | 1 | 1995 | 7 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 1995 | 102 | 0.010 |
Why?
|
Cholesterol, Dietary | 1 | 1994 | 10 | 0.010 |
Why?
|
Tape Recording | 1 | 1994 | 6 | 0.010 |
Why?
|
Computers | 1 | 1994 | 7 | 0.010 |
Why?
|
Lipoproteins | 1 | 1993 | 14 | 0.010 |
Why?
|
Skinfold Thickness | 1 | 1992 | 18 | 0.010 |
Why?
|
Hospitalization | 1 | 1998 | 847 | 0.010 |
Why?
|
Nutritional Requirements | 1 | 1991 | 6 | 0.010 |
Why?
|
Hyperkinesis | 1 | 1980 | 1 | 0.000 |
Why?
|